Synaffix, a biotechnology company, has entered a technology agreement with MacroGenics, a developer of monoclonal antibody-based cancer therapeutics, through which MacroGenics will gain access to Synaffix’s clinical stage GlycoConnect antibody conjugation technology.
The company will also license Synaffix’s HydraSpace polar spacer technology, as well as select toxSYN linker-payloads, designed to enable ADCs with high efficacy and tolerability. These will be combined with MacroGenics’ proprietary antibody and bispecific DART antibody platform technologies for the generation of ADCs.
Under the agreement, Synaffix will be eligible to receive up to $586m in payments. The first programme will begin at signature, with the option to expand the collaboration to a further two programmes by March 2023.
MacroGenics will be responsible for the research, development, manufacturing and commercialisation phases of each programme, while Synaffix will support research activities and be responsible for the manufacturing of components specifically related to its proprietary technologies.
Ezio Bonvini, CSO of MacroGenics, saod: “We are delighted to be working with Synaffix to produce next generation ADCs with potentially superior therapeutic properties. The ability to obtain all essential ADC technologies from Synaffix, and easily and rapidly combine those with our antibody-based molecules, will enable us to expand our existing portfolio of ADC product candidates and further strengthen our position in the growing ADC field.”
Peter van de Sande, CEO of Synaffix, said: “The collaboration with MacroGenics is an important milestone for Synaffix as our ADC technology will be deployed for the generation of both monospecific and bispecific ADCs. We are pleased to further expand the use of our technology with another leading biotech company that has deep product development capabilities and a long-term commitment to delivering novel therapies for the treatment of cancer.”